Clariant Opens New Innovation Center in Frankfurt - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Clariant Opens New Innovation Center in Frankfurt

Untitled Document

Clariant, a provider of fine and specialty chemicals, has opened its new EUR 100 million ($134 million) Clariant Innovation Center (CIC) in Frankfurt, Germany. The company’s new global hub for R&D is based at the “Industriepark Höchst.” It will be the home of Clariant’s competence centers in chemical research and process technology as well as application laboratories for several business units and analytical laboratories. The CIC will also house the departments for Intellectual Property Management and New Business Development. As the corporation’s global hub, the CIC will coordinate Clariant’s R&D network, which includes centers across Europe, North America, Brazil, Japan, India, and China. The new facility covers a total surface area of 36,000 m2 and will house around 500 employees from R&D and support business and administrative functions. It features a mix of open workspaces, offices, and laboratories.

Source: Clariant


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here